Paclitaxel injection — Competitive Intelligence Brief

Paclitaxel injection (Paclitaxel injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

marketed Taxane; microtubule stabilizer β-tubulin Oncology Small molecule

Target snapshot

Paclitaxel injection (Paclitaxel injection) — Guangzhou Double Bioproducts Co., Ltd. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paclitaxel injection TARGET	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin
ZENTEL and Vitamin A Soft Capsules	ZENTEL and Vitamin A Soft Capsules	Chengdu Maternal and Children's Health Care Hospital	marketed	Anthelmintic + Vitamin supplement	β-tubulin (albendazole component)
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Administration of Albendazole on Day 1	Administration of Albendazole on Day 1	London School of Hygiene and Tropical Medicine	marketed	Benzimidazole anthelmintic	β-tubulin
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

1. Sanofi · 2 drugs in this class
2. Aravive, Inc. · 1 drug in this class
3. Athenex, Inc. · 1 drug in this class
4. Barts & The London NHS Trust · 1 drug in this class
5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
6. Bio-Thera Solutions · 1 drug in this class
7. Dai, Guanghai · 1 drug in this class
8. Fujian Medical University · 1 drug in this class
9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class